Skip to main content
SpringerLink
Log in

General Statement as to Efficacy of Surgery, Chemotherapy, Radiation Therapy, and Immunotherapy

  • Chapter
  • First Online:
Management of Soft Tissue Sarcoma

  • 1568 Accesses

Abstract

The principal management of primary soft tissue sarcoma is surgical resection. The clinical goal is resection with negative margins, preferably that extend 2 cm from the grossly determined border. This can be difficult to assess and is often limited by the presence of major neurovascular and bony structures. The majority of soft tissue sarcomas do not invade into bone unless there has been previous injury to bone or the lesion has an epithelioid component, such as synovial sarcoma.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 199.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Suzman MS, Smith AJ, Brennan MF. Fascio-peritoneal patch repair of the IVC: a workhorse in search of work? J Am Coll Surg. 2000;191:218–20.

    Article  CAS  PubMed  Google Scholar 

  2. Hollenbeck ST, Grobmyer SR, Kent KC, et al. Surgical treatment and outcomes of patients with primary inferior vena cava leiomyosarcoma. J Am Coll Surg. 2003;197:575–9.

    Article  PubMed  Google Scholar 

  3. Russo P, Kim Y, Ravindran S, et al. Nephrectomy during operative management of retroperitoneal sarcoma. Ann Surg Oncol. 1997;4:421–4.

    Article  CAS  PubMed  Google Scholar 

  4. Gronchi A, Bonvalot S, Le Cesne A, et al. Resection of uninvolved adjacent organs can be part of surgery for retroperitoneal soft tissue sarcoma. J Clin Oncol. 2009;27:2106–7; author reply 2107-8.

    Article  PubMed  Google Scholar 

  5. Duranti L, Gronchi A, Stacchiotti S, et al. Localised thoracic sarcomas: outcome improvement over time at a single institution. Eur J Cancer. 2013;49:2689–97.

    Article  PubMed  Google Scholar 

  6. Stacchiotti S, Crippa F, Messina A, et al. Response to imatinib in villonodular pigmented synovitis (PVNS) resistant to nilotinib. Clin Sarcoma Res. 2013;3:8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Gronchi A, Lo Vullo S, Fiore M, et al. Aggressive surgical policies in a retrospectively reviewed single-institution case series of retroperitoneal soft tissue sarcoma patients. J Clin Oncol. 2009;27:24–30.

    Article  PubMed  Google Scholar 

  8. Brennan MF, Lewis JJ. Diagnosis and Management of Soft Tissue Sarcoma. London: Martin Dunitz Ltd.; 2002.

    Google Scholar 

  9. Eilber FC, Brennan MF, Riedel E, et al. Prognostic factors for survival in patients with locally recurrent extremity soft tissue sarcomas. Ann Surg Oncol. 2005;12:228–36.

    Article  PubMed  Google Scholar 

  10. Panicek DM, Gatsonis C, Rosenthal DI, et al. CT and MR imaging in the local staging of primary malignant musculoskeletal neoplasms: Report of the Radiology Diagnostic Oncology Group. Radiology. 1997;202:237–46.

    Article  CAS  PubMed  Google Scholar 

  11. Fazel R, Krumholz HM, Wang Y, et al. Exposure to low-dose ionizing radiation from medical imaging procedures. N Engl J Med. 2009;361:849–57.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Benz MR, Dry SM, Eilber FC, et al. Correlation between glycolytic phenotype and tumor grade in soft-tissue sarcomas by 18F-FDG PET. J Nucl Med. 2010;51:1174–81.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Eary JF, Conrad EU. PET imaging: update on sarcomas. Oncology (Williston Park). 2007;21:249–52.

    Google Scholar 

  14. Schuetze SM. Utility of positron emission tomography in sarcomas. Curr Opin Oncol. 2006;18:369–73.

    Article  PubMed  Google Scholar 

  15. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25:1753–9.

    Article  PubMed  Google Scholar 

  16. Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol. 2007;25:1760–4.

    Article  PubMed  Google Scholar 

  17. Gadd MA, Casper ES, Woodruff JM, et al. Development and treatment of pulmonary metastases in adult patients with extremity soft tissue sarcoma. Ann Surg. 1993;218:705–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Mountain CF, McMurtrey MJ, Hermes KE. Surgery for pulmonary metastasis: a 20-year experience. Ann Thorac Surg. 1984;38:323–30.

    Article  CAS  PubMed  Google Scholar 

  19. Billingsley KG, Burt ME, Jara E, et al. Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann Surg. 1999;229:602–10; discussion 610–2.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Weiser MR, Downey RJ, Leung DH, et al. Repeat resection of pulmonary metastases in patients with soft-tissue sarcoma. J Am Coll Surg. 2000;191:184–90; discussion 190-1.

    Article  CAS  PubMed  Google Scholar 

  21. Temple LK, Brennan MF. The role of pulmonary metastasectomy in soft tissue sarcoma. Semin Thorac Cardiovasc Surg. 2002;14:35–44.

    Article  PubMed  Google Scholar 

  22. Canter RJ, Qin LX, Downey RJ, et al. Perioperative chemotherapy in patients undergoing pulmonary resection for metastatic soft-tissue sarcoma of the extremity : a retrospective analysis. Cancer. 2007;110:2050–60.

    Article  PubMed  Google Scholar 

  23. DeMatteo RP, Shah A, Fong Y, et al. Results of hepatic resection for sarcoma metastatic to liver. Ann Surg. 2001;234:540–7; discussion 547–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Pisters PW, Harrison LB, Leung DH, et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol. 1996;14:859–68.

    CAS  PubMed  Google Scholar 

  25. Yang JC, Chang AE, Baker AR, et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol. 1998;16:197–203.

    CAS  PubMed  Google Scholar 

  26. Alektiar KM, Leung D, Zelefsky MJ, et al. Adjuvant radiation for stage II-B soft tissue sarcoma of the extremity. J Clin Oncol. 2002;20:1643–50.

    Article  PubMed  Google Scholar 

  27. Cahlon O, Brennan MF, Jia X, et al. A postoperative nomogram for local recurrence risk in extremity soft tissue sarcomas after limb-sparing surgery without adjuvant radiation. Ann Surg. 2012;255:343–7.

    Article  PubMed  PubMed Central  Google Scholar 

  28. O'Sullivan B, Davis AM, Turcotte R, et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359:2235–41.

    Article  PubMed  Google Scholar 

  29. Davis AM, O'Sullivan B, Turcotte R, et al. Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma. Radiother Oncol. 2005;75:48–53.

    Article  PubMed  Google Scholar 

  30. Alektiar KM, Hong L, Brennan MF, et al. Intensity modulated radiation therapy for primary soft tissue sarcoma of the extremity: preliminary results. Int J Radiat Oncol Biol Phys. 2007;68:458–64.

    Article  PubMed  Google Scholar 

  31. Alektiar KM, Brennan MF, Singer S. Local control comparison of adjuvant brachytherapy to intensity-modulated radiotherapy in primary high-grade sarcoma of the extremity. Cancer. 2011;117:3229–34.

    Article  PubMed  Google Scholar 

  32. Folkert MR, Singer S, Brennan MF, et al. Comparison of local recurrence with conventional and intensity-modulated radiation therapy for primary soft-tissue sarcomas of the extremity. J Clin Oncol. 2014;32:3236–41.

    Article  PubMed  PubMed Central  Google Scholar 

  33. Alektiar KM, Leung D, Zelefsky MJ, et al. Adjuvant brachytherapy for primary high-grade soft tissue sarcoma of the extremity. Ann Surg Oncol. 2002;9:48–56.

    Article  PubMed  Google Scholar 

  34. Ormsby MV, Hilaris BS, Nori D, et al. Wound complications of adjuvant radiation therapy in patients with soft-tissue sarcomas. Ann Surg. 1989;210:93–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Arbeit JM, Hilaris BS, Brennan MF. Wound complications in the multimodality treatment of extremity and superficial truncal sarcomas. J Clin Oncol. 1987;5:480–8.

    CAS  PubMed  Google Scholar 

  36. Alekhteyar KM, Leung DH, Brennan MF, et al. The effect of combined external beam radiotherapy and brachytherapy on local control and wound complications in patients with high-grade soft tissue sarcomas of the extremity with positive microscopic margin. Int J Radiat Oncol Biol Phys. 1996;36:321–4.

    Article  CAS  PubMed  Google Scholar 

  37. Alektiar KM, Zelefsky MJ, Brennan MF. Morbidity of adjuvant brachytherapy in soft tissue sarcoma of the extremity and superficial trunk. Int J Radiat Oncol Biol Phys. 2000;47:1273–9.

    Article  CAS  PubMed  Google Scholar 

  38. Al Yami A, Griffin AM, Ferguson PC, et al. Positive surgical margins in soft tissue sarcoma treated with preoperative radiation: is a postoperative boost necessary? Int J Radiat Oncol Biol Phys. 2010;77:1191–7.

    Article  PubMed  Google Scholar 

  39. Shiu MH, Collin C, Hilaris BS, et al. Limb preservation and tumor control in the treatment of popliteal and antecubital soft tissue sarcomas. Cancer. 1986;57:1632–9.

    Article  CAS  PubMed  Google Scholar 

  40. Alektiar KM, Brennan MF, Singer S. Influence of site on the therapeutic ratio of adjuvant radiotherapy in soft-tissue sarcoma of the extremity. Int J Radiat Oncol Biol Phys. 2005;63:202–8.

    Article  PubMed  Google Scholar 

  41. Spierer MM, Alektiar KM, Zelefsky MJ, et al. Tolerance of tissue transfers to adjuvant radiation therapy in primary soft tissue sarcoma of the extremity. Int J Radiat Oncol Biol Phys. 2003;56:1112–6.

    Article  PubMed  Google Scholar 

  42. Rimner A, Brennan MF, Zhang Z, et al. Influence of compartmental involvement on the patterns of morbidity in soft tissue sarcoma of the thigh. Cancer. 2009;115:149–57.

    Article  PubMed  Google Scholar 

  43. Gortzak Y, Lockwood GA, Mahendra A, et al. Prediction of pathologic fracture risk of the femur after combined modality treatment of soft tissue sarcoma of the thigh. Cancer. 2010;116:1553–9.

    Article  PubMed  Google Scholar 

  44. Dickie CI, Parent AL, Griffin AM, et al. Bone fractures following external beam radiotherapy and limb-preservation surgery for lower extremity soft tissue sarcoma: relationship to irradiated bone length, volume, tumor location and dose. Int J Radiat Oncol Biol Phys. 2009;75:1119–24.

    Article  PubMed  Google Scholar 

  45. Kepka L, DeLaney TF, Suit HD, et al. Results of radiation therapy for unresected soft-tissue sarcomas. Int J Radiat Oncol Biol Phys. 2005;63:852–9.

    Article  PubMed  Google Scholar 

  46. Dhakal S, Corbin KS, Milano MT, et al. Stereotactic body radiotherapy for pulmonary metastases from soft-tissue sarcomas: excellent local lesion control and improved patient survival. Int J Radiat Oncol Biol Phys. 2012;82:940–5.

    Article  PubMed  Google Scholar 

  47. Navarria P, Ascolese AM, Cozzi L, et al. Stereotactic body radiation therapy for lung metastases from soft tissue sarcoma. Eur J Cancer. 2015;51:668–74.

    Article  PubMed  Google Scholar 

  48. Folkert MR, Bilsky MH, Tom AK, et al. Outcomes and toxicity for hypofractionated and single-fraction image-guided stereotactic radiosurgery for sarcomas metastasizing to the spine. Int J Radiat Oncol Biol Phys. 2014;88:1085–91.

    Article  PubMed  Google Scholar 

  49. Sarcoma Meta-Analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet. 1997;350:1647–54.

    Article  Google Scholar 

  50. Omura GA, Blessing JA, Major F, et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. J Clin Oncol. 1985;3:1240–5.

    CAS  PubMed  Google Scholar 

  51. Pautier P, Floquet A, Gladieff L, et al. A randomized clinical trial of adjuvant chemotherapy with doxorubicin, ifosfamide, and cisplatin followed by radiotherapy versus radiotherapy alone in patients with localized uterine sarcomas (SARCGYN study). A study of the French Sarcoma Group. Ann Oncol. 2013;24:1099–104.

    Article  CAS  PubMed  Google Scholar 

  52. Hensley ML, Ishill N, Soslow R, et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study. Gynecol Oncol. 2009;112:563–7.

    Article  CAS  PubMed  Google Scholar 

  53. Clinicaltrials.gov: Study NCT00282087.

    Google Scholar 

  54. Hensley ML, Wathen JK, Maki RG, et al. Adjuvant therapy for high-grade, uterus-limited leiomyosarcoma: results of a phase 2 trial (SARC 005). Cancer. 2013;119:1555–61.

    Article  CAS  PubMed  Google Scholar 

  55. Alvegard TA, Sigurdsson H, Mouridsen H, et al. Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group. J Clin Oncol. 1989;7:1504–13.

    CAS  PubMed  Google Scholar 

  56. Bramwell V, Rouesse J, Steward W, et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma--reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1994;12:1137–49.

    CAS  PubMed  Google Scholar 

  57. Frustaci S, Gherlinzoni F, De Paoli A, et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol. 2001;19:1238–47.

    CAS  PubMed  Google Scholar 

  58. Gortzak E, Azzarelli A, Buesa J, et al. A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer. 2001;37:1096–103.

    Article  CAS  PubMed  Google Scholar 

  59. Brodowicz T, Schwameis E, Widder J, et al. Intensified Adjuvant IFADIC Chemotherapy for Adult Soft Tissue Sarcoma: A Prospective Randomized Feasibility Trial. Sarcoma. 2000;4:151–60.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Woll PJ, Reichardt P, Le Cesne A, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol. 2012; 13:1045–54.

    Google Scholar 

  61. Gronchi A, Ferrari S, Quagliuolo et al. LBSA6_PR: Full-dose neoadjuvant anthracycline + ifosfamide chemotherpay is associated with a relapse free survival and overall survival benefit in localized high-risk adult soft tissue sarcomas of the extremities and trunk wall: Interim analysis of prospective randomized trial. Proc ESMO 2016, Abstract LBA6.

    Google Scholar 

  62. SM-A Sarcoma Meta-analysis collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet. 1997;350:1647–54.

    Google Scholar 

  63. Pervaiz N, Colterjohn N, Farrokhyar F, et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113:573–81.

    Google Scholar 

  64. Toulmonde M, Bellera C, Mathoulin-Pelissier S, et al. Quality of randomized controlled trials reporting in the treatment of sarcomas. J Clin Oncol. 2011;29:1204–9.

    Article  PubMed  Google Scholar 

  65. Le Cesne A, Ouali M, Leahy MG, et al. Doxorubicin-based adjuvant chemotherapy in soft tissue sarcoma: pooled analysis of two STBSG-EORTC phase III clinical trials. Ann Oncol. 2014;25:2425–32.

    Article  PubMed  Google Scholar 

  66. DeMatteo RP, Ballman KV, Antonescu CR, Corless C, Kolesnikova V, von Mehren M, McCarter MD, Norton J, Maki RG, Pisters PW, Demetri GD, Brennan MF, Owzar K. Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (Alliance) intergroup phase 2 trial. Ann Surg. 2013; 258:422–9.

    Google Scholar 

  67. Dematteo RP, Ballman KV, Antonescu CR, et al. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:1097–104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Casali PG, Le Cesne A, Poveda Velasco A, et al. Imatinib failure-free survival (IFS) in patients with localized gastrointestinal stromal tumors (GIST) treated with adjuvant imatinib (IM): The EORTC/AGITG/FSG/GEIS/ISG randomized controlled phase III trial. ASCO Meeting Abstracts. 2013;31:10500.

    Google Scholar 

  69. Joensuu H, Eriksson M, Sundby Hall K, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial. JAMA. 2012;307:1265–72.

    Article  CAS  PubMed  Google Scholar 

  70. Corless CL, Ballman KV, Antonescu CR, et al. Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial. J Clin Oncol. 2014; 32:1563–70.

    Google Scholar 

  71. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med. 2003;348:694–701.

    Article  CAS  PubMed  Google Scholar 

  72. Womer RB, West DC, Krailo MD, et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012;30:4148–54.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Granowetter L, Womer R, Devidas M, et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children's Oncology Group Study. J Clin Oncol. 2009;27:2536–41.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Crist WM, Anderson JR, Meza JL, et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J Clin Oncol. 2001;19:3091–102.

    CAS  PubMed  Google Scholar 

  75. Antman K, Crowley J, Balcerzak SP, et al. A Southwest Oncology Group and Cancer and Leukemia Group B phase II study of doxorubicin, dacarbazine, ifosfamide, and mesna in adults with advanced osteosarcoma, Ewing's sarcoma, and rhabdomyosarcoma. Cancer. 1998;82:1288–95.

    Article  CAS  PubMed  Google Scholar 

  76. Talbot SM, Keohan ML, Hesdorffer M, et al. A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. Cancer. 2003;98:1942–6.

    Article  CAS  PubMed  Google Scholar 

  77. Garcia del Muro X, Lopez-Pousa A, Martin J, et al. A phase II trial of temozolomide as a 6-week, continuous, oral schedule in patients with advanced soft tissue sarcoma: a study by the Spanish Group for Research on Sarcomas. Cancer. 2005;104:1706–12.

    Article  CAS  PubMed  Google Scholar 

  78. Boyar MS, Hesdorffer M, Keohan ML, et al. Phase II Study of Temozolomide and Thalidomide in Patients with Unresectable or Metastatic Leiomyosarcoma. Sarcoma. 2008;2008:412503.

    Article  PubMed  PubMed Central  Google Scholar 

  79. Fury MG, Antonescu CR, Van Zee KJ, et al. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J. 2005;11:241–7.

    Article  PubMed  Google Scholar 

  80. Penel N, Italiano A, Ray-Coquard I, et al. Metastatic angiosarcomas: doxorubicin-based regimens, weekly paclitaxel and metastasectomy significantly improve the outcome. Ann Oncol. 2012;23:517–23.

    Article  CAS  PubMed  Google Scholar 

  81. Italiano A, Cioffi A, Penel N, et al. Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer. 2012;118:3330–6.

    Article  CAS  PubMed  Google Scholar 

  82. Bramwell VH, Mouridsen HT, Santoro A, et al. Cyclophosphamide versus ifosfamide: final report of a randomized phase II trial in adult soft tissue sarcomas. Eur J Cancer Clin Oncol. 1987;23:311–21.

    Article  CAS  PubMed  Google Scholar 

  83. Rosen G, Forscher C, Lowenbraun S, et al. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer. 1994;73:2506–11.

    Article  CAS  PubMed  Google Scholar 

  84. Ryan CW, Schoffski P, Merimsky O, et al. PICASSO 3: A phase 3 international, randomized, double-blind, placebo-controlled study of doxorubicin (dox) plus palifosfamide (pali) vs. dox plus placebo for patients (pts) in first-line for metastatic soft tissue sarcoma (mSTS). Eur J Cancer. 2013;49:876.

    Google Scholar 

  85. Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;20:2824–31.

    Article  CAS  PubMed  Google Scholar 

  86. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 2007;25:2755–63.

    Article  CAS  PubMed  Google Scholar 

  87. Demetri GD, von Mehren M, Jones RL, et al. Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. J Clin Oncol. 2016; 34: 786-93.

    Google Scholar 

  88. Sch&ffski P, Chawla S, Maki RG, et al. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016; 387:1629–37.

    Google Scholar 

  89. van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379:1879–86.

    Article  PubMed  Google Scholar 

  90. Chawla SP, Chua VS, Hendifar AF, et al. A phase 1B/2 study of aldoxorubicin in patients with soft tissue sarcoma. Cancer. 2015;121:570–9.

    Article  CAS  PubMed  Google Scholar 

  91. Chawla SP, Cranmer LD, Van Tine BA, et al. Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma. J Clin Oncol. 2014;32:3299–306.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. 2016. Lancet. 388:488–97.

    Google Scholar 

  93. Mason M, Robinson M, Harmer C, et al. Intra-arterial adriamycin, conventionally fractionated radiotherapy and conservative surgery for soft tissue sarcomas. Clin Oncol (R Coll Radiol). 1992;4:32–5.

    Article  CAS  Google Scholar 

  94. Eggermont AM, Schraffordt Koops H, Lienard D, et al. Isolated limb perfusion with high-dose tumor necrosis factor-alpha in combination with interferon-gamma and melphalan for nonresectable extremity soft tissue sarcomas: a multicenter trial. J Clin Oncol. 1996;14:2653–65.

    CAS  PubMed  Google Scholar 

  95. Eggermont AM, de Wilt JH, ten Hagen TL. Current uses of isolated limb perfusion in the clinic and a model system for new strategies. Lancet Oncol. 2003;4:429–37.

    Article  PubMed  Google Scholar 

  96. Hoven-Gondrie ML. Bastiaannet E, van Ginkel RJ, et al: [Limb perfusion in soft tissue sarcomas: twenty years of experience]. Ned Tijdschr Geneeskd. 2013;157:A6148.

    PubMed  Google Scholar 

  97. Wiedemann GJ, d'Oleire F, Knop E, et al. Ifosfamide and carboplatin combined with 41.8 degrees C whole-body hyperthermia in patients with refractory sarcoma and malignant teratoma. Cancer Res. 1994;54:5346–50.

    CAS  PubMed  Google Scholar 

  98. Wendtner CM, Abdel-Rahman S, Krych M, et al. Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. J Clin Oncol. 2002;20:3156–64.

    Article  CAS  PubMed  Google Scholar 

  99. Issels RD, Abdel-Rahman S, Wendtner C, et al. Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study. Eur J Cancer. 2001;37:1599–608.

    Article  CAS  PubMed  Google Scholar 

  100. Issels RD, Lindner LH, Verweij J, et al. Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study. Lancet Oncol. 2010;11:561–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. J Clin Oncol. 2008;26:633–8.

    Article  CAS  PubMed  Google Scholar 

  102. Tawbi H, Burgess MA, Crowley J, et al. Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft tissue and bone sarcomas: Results of SARC028--A multicenter phase II study. ASCO Meeting Abstracts. 2016;34:11006.

    Google Scholar 

  103. Paoluzzi L, Ghesani MV, Cacavio A, et al. Anti-PD1 therapy with nivolumab in sarcoma. ASCO Meeting Abstracts. 2016;34:11047.

    Google Scholar 

  104. Robbins PF, Kassim SH, Tran TL, et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin Cancer Res. 2015;21:1019–27.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. International Center Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Murray F. Brennan MD

  2. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Cristina R. Antonescu MD

  3. Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Kaled M. Alektiar MD

  4. Monter Cancer Center, Hofstra Northwell School of Medicine and Cold Spring Harbor Laboratory, Lake Success, NY, USA

    Robert G. Maki MD, PhD

Authors
  1. Murray F. Brennan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cristina R. Antonescu MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kaled M. Alektiar MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert G. Maki MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Brennan, M.F., Antonescu, C.R., Alektiar, K.M., Maki, R.G. (2016). General Statement as to Efficacy of Surgery, Chemotherapy, Radiation Therapy, and Immunotherapy. In: Management of Soft Tissue Sarcoma. Springer, Cham. https://doi.org/10.1007/978-3-319-41906-0_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-41906-0_3

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-41904-6

  • Online ISBN: 978-3-319-41906-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation